ICON Public Limited Company

NASDAQ:ICLR

Medical - Diagnostics & Research

Healthcare
$195.16 -0.19%

-$0.27 today

Market cap
$14.62B
Beta
1.27
P/E (TTM)
23.0
EPS (TTM)
$6.23
52W Low $66.57High $211.00

Volume 0.55M

Average 1.15M

ICLR EBITDA Margin

EBITDA as a percentage of revenue.

ICON Public Limited CompanyNASDAQ: ICLR

EBITDA Margin · Q2 FY2026 · quarter ended Jun 2026

EBITDA Margin narrows to 14.2%

EBITDA Margin was 14.2% in Q2 FY2026, down 1.1 pp from a year earlier. On a trailing-twelve-month basis it was 15.1%, down 1.9 pp year over year. Over 3 fiscal years it narrowed by 7.7 pp.

Context

  • EBITDA Margin widened in 2 of the last 3 fiscal years.
  • FY2025 was the lowest level in the 4 fiscal years shown.

What to watch

Whether EBITDA Margin reaches the consensus estimate from 13 analysts of 18.7% for the fiscal year ending Dec 2026, up from 10.0% in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterJun 2026
14.2%+0.6 pp QoQ
Last fiscal yearDec 2025
10.0%-8.9 pp YoY
LTMJun 2026
15.1%-1.9 pp YoY
EBITDA Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter-1.1 pp+10.9 pp+12.0 pp
1 year-8.9 pp+8.8 pp+17.7 pp
3 years-7.7 pp+7.9 pp+15.6 pp
5 years+8.8 pp—
10 years——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

EBITDA Margin history

Percent of revenue · from the income statement

Latest · FY2025
10.0%
Year-over-year change
-8.9pp
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

EBITDA Margin vs competitors

How ICLR compares with its peers on the latest reported figures

  • ICLR's LTM Jun 2026 EBITDA Margin of 15.1% is the 3rd highest of the 6 companies compared; the peer median is 15.0%.
  • Its year-over-year change of -1.9 pp is the 5th highest of 6, against a peer median of -0.6 pp.
  • Over three fiscal years its change of -7.7 pp compares with a peer median of -2.2 pp.
ICLR Competitors Peer median
EBITDA Margin for ICLR and competitors
Company Period LTM level YoY 3-year change
MEDPMedpace Holdings, Inc.LTM Sep 202622.7% -0.6 pp+1.4 pp
IQVIQVIA Holdings Inc.LTM Jun 202620.8% -0.6 pp-2.2 pp
ICLRICON Public Limited CompanyLTM Jun 202615.1% -1.9 pp-7.7 pp
LHLabcorp Holdings Inc.LTM Jun 202615.0% +1.1 pp-2.0 pp
CRLCharles River Laboratories International, Inc.LTM Jun 20265.5% -7.6 pp-14.6 pp
FTREFortrea Holdings Inc.LTM Jun 20263.0% +34.4 pp-39.8 pp
Peer median (excluding ICLR) 15.0%-0.6 pp-2.2 pp

Competitors are the stored peer set for ICLR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue5.48B7.74B8.12B8.28B8.25B
Cost of Revenue3.97B5.53B5.72B5.85B6.08B
Gross Profit1.51B2.21B2.4B2.44B2.18B
Gross Margin27.5%28.6%29.6%29.4%26.4%
Research & Development00000
Selling, General & Admin585.33M778.75M776.36M728.35M780.14M
Operating Expenses1.13B1.42B1.44B1.34B1.16B
Depreciation & Amortization314.99M569.51M585.95M488.5M383M
EBITDA694.09M1.37B1.52B1.56B823.57M
EBITDA Margin12.7%17.7%18.7%18.9%10.0%
Operating Income378.53M795.24M956.15M1.1B1.01B
Operating Margin6.9%10.3%11.8%13.3%12.3%
Interest Income574K2.35M5.01M8.61M7.11M
Interest Expense182.42M229.73M336.7M237.24M188.11M
Other Income / Expenses(184.01M)(230.52M)(331.69M)(228.63M)(759.99M)
Income Before Tax194.52M564.72M624.08M869.18M252.47M
Pre-Tax Margin3.5%7.3%7.7%10.5%3.1%
Income Tax Expense41.33M59.41M11.75M77.71M23.13M
Net Income153.19M505.3M612.34M791.47M229.34M
Net Margin2.8%6.5%7.5%9.6%2.8%
EPS (Basic)2.286.207.469.602.92
EPS (Diluted)2.256.137.409.532.90
Weighted Avg Shares67.11M81.53M82.1M82.48M78.42M
Weighted Avg Shares (Diluted)68.07M82.47M82.72M83.03M78.97M

ICON Public Limited Company

NASDAQ:ICLR

Intrinsic Alpha fair value

Locked

Current Price

$195.16

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.